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Objectives: To determine whether patch angioplasty is more effective than primary closure in carotid endarterectomy, 
and whether one type of patch is better than another. 
Design: Systematic review of the randomised trials. 
Materials: Trials were identified from the Cochrane Stroke Review Group database plus additional handsearching, 
electronic searching, and personal contact. 
Methods: Two authors independently selected studies for inclusion and extracted details of trial quality and data on the 
following outcomes: any stroke; stroke ipsilateral to the operated artery; death; occlusion or restenosis, and other significant 
arterial complications. Meta-analysis ofodds ratios (OR) was performed using the Peto method. 
Results: Six trials (882 operations) compared routine patching with primary closure. Routine patching was associated 
with significant reductions in the risks of ipsilateral stroke during the perioperative p riod (OR 0.34, 95% CI 0.15-0.76) 
and during long-term follow-up (OR 0.38, 95% CI 0.16-0.88). Significant reductions in the odds of any stroke, stroke 
or death, acute arterial occlusion and long-term restenosis were also found. However, these results were based on very 
small numbers of outcome vents and may be biased by losses to follow-up and publication bias. Three trials (326 
operations) compared the use of polytetrafluoroethylene patches with venous patches. There were too few events (strokes, 
deaths, arterial complications) to determine whether there were signifi'cant differences between the patch materials. Fewer 
pseudoaneurysms occurred in those who received synthetic patches but the clinical consequence of this was unclear. 
Conclusions: Routine carotid patch angioplasty was associated with promising reductions in the risks of ipsilateral stroke 
and death, but the results hould be interpreted cautiously because of the small number of outcome vents, significant 
losses to folIow-up, and poor trial methodology. Ideally, a large defi'nitive trial should be performed. There is insufficient 
evidence to support he preferential use of one particular type of patch versus another. 
Introduction 
Carotid endarterectomy has been shown in large, well 
conducted randomised controlled trials to reduce the 
risk of stroke in patients with recently symptomatic, 
severe (>70%) internal carotid artery stenosis. 1"2 What 
is unclear at present is whether different surgical 
techniques affect the outcome. One such issue is 
whether the use of carotid patch angioplasty reduces 
the risk of early arterial occlusion and long term 
restenosis and, more importantly, reduces peri- 
operative and long-term stroke ipsilateral to the op- 
erated artery (ipsilateral stroke). 
*Please address all correspondence to: Dr Carl Counsell, De- 
partment of Clinical Neurosciences, Western General Hospital, 
Crewe Road, Edinburgh EH4 2XU, U.K. 
Studies uggest that greater than 50% restenosis of 
the carotid artery occurs in 6-36% of patients following 
endarterectomy. 3-7 The risk of symptomatic restenosis 
appears to be much lower, about 2-4% over 5 years. 8
Carotid patch angioplasty may reduce the risk of 
restenosis, and so, hopefully, reduce the long-term risk 
of recurrent ipsilateral ischaemic stroke. 4'9 However, it 
may also be associated with certain perioperative risks. 
Patching involves a longer carotid occlusion time, two 
suture lines instead of one and the use of a patch 
material, all of which may increase the risk of early 
re-occlusion, arterial rupture, infection or pseudo- 
aneurysm formation. 9'1° In addition, if a venous patch 
is used, there may be some morbidity associated with 
vein harvesting, such as persistent pain. 
Surveys from the U.K. and the U.S.A. have shown 
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considerable variations among vascular surgeons in 
the use of carotid patching which may reflect un- 
certainty in its benefits: in the U.K., 21% of surgeons 
always used patching and 50% rarely or never did, 11 
whilst in the U.S.A. only 16% of patients undergoing 
carotid endarterectomy received a patch. ~2 For those 
surgeons who use a patch, there is also uncertainty as 
to which type of patch is best. 13 Venous patching 
(usually from the saphenous vein in the groin) is 
favoured by some on the basis that a non-randomised 
comparison suggested that it was better at preventing 
stroke or death. ~2 It also has the advantages of being 
easily available and easy to handle. Synthetic material, 
such as Dacron or polytetrafluoroethylene (PTFE), is 
favoured by others who feel that it offers a lower risk 
of patch rupture ~1 and aneurysmal dilatation, 14 it spares 
the morbidity associated with vein harvesting and 
leaves the vein which may be required for coronary 
bypass grafting later. All prosthetic patches, however, 
are susceptible to the small, but devastating, risk of 
infection. 
As for other interventions, the best evidence on the 
efficacy of patching is likely to come from randomised 
controlled trials (RCTs). We, therefore, performed a 
systematic review of all the RCTs that compared a 
policy of routine patching (i.e. patching attempted 
in all patients) or selective patching (i.e. patching 
attempted only in patients thought likely to benefit 
such as those with narrow arteries) with primary 
closure, or compared one type of patch with another. 
Our primary hypothesis was that carotid patch an- 
gioplasty resulted in a lower rate of arterial restenosis 
and therefore fewer recurrent ipsilateral strokes with- 
out a significant increase in perioperative com- 
plications. 
envelopes) were included. However, since fore- 
knowledge of treatment allocation can lead to biased 
treatment allocation and exaggerated treatment ef- 
fects, is we also planned to perform separate analyses 
excluding such quasi-random trials. Patients of all ages 
and either sex were considered eligible, regardless 
of whether the indication for endarterectomy was 
symptomatic or asymptomatic carotid disease. 
Search strategy 
We identified relevant rials from the Cochrane Stroke 
Group's trials' register, 16 a database produced by on- 
going searching of MEDLINE, 20 journals relevant o 
stroke (including Neurosurgery, Surgical Neurology and 
The Journal of Vascular Surgery), conference pro- 
ceedings, reference lists, the Ottawa Stroke Trials Re- 
gister, 17 and dissertation abstracts. Additional searches 
included: searching the Annals of Surgery (1981-1995), 
the British Journal of Surgery (1985-1996), the European 
Journal of Vascular and Endovascular Surgery (1987- 
1995), and the World Journal of Surgery (1978-1995) by 
hand; performing more detailed searching of MED- 
LINE from 1966-1995 using the term 'carotid en- 
darterectomy', of EMBASE from 1980-1995 using the 
terms 'carotid endarterectomy' and 'carotid surgery', 
and of The Index to Scientific and Technical Pro- 
ceedings - a database of conference proceedings - 
from 1980-1994 using the term 'carotid'; searching the 
reference lists of additional studies we found; writing 
to the authors of all the trials that we identified to 
ask if they knew of other trials that we had missed, 
particularly unpublished trials. 
Material and Methods 
Inclusion criteria 
We sought to identify all randomised or quasi-ran- 
domised trials that compared routine carotid patching 
with any type of patch with primary closure in carotid 
endarterectomy or that compared closure with one 
type of patch with another. We also planned to include 
trials of selective patch angioplasty with primary clos- 
ure, but we failed to identify any such trials. Quasi- 
random trials (e.g. allocation by alternation, date of 
birth, hospital number, day of the week) or randomised 
trials in which allocation to different treatment re- 
gimens was not adequately concealed (e.g. using an 
open random number list or non-opaque, unsealed 
Data extraction 
Two reviewers (RS, CC) independently selected which 
trials were to be included in the review. Disagreements 
were resolved by discussion. The methodological qual- 
ity of each trial was assessed by the same two reviewers 
by recording the randomisation method, the blinding 
of the clinical and Doppler assessments o treatment 
allocation, and how many patients were excluded after 
randomisation orlost to follow-up. We tried to identify 
from each trial the number of patients and arteries ori- 
ginally randomised to each treatment group and the 
outcomes in all randomised patients to allow an in- 
tention-to-treat nalysis. For each treatment group we 
counted the number of patients: (a) who died within 30 
days of the operation and during subsequent follow- 
up. We classified eaths as stroke-related or not; (b) who 
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had any stroke and only ipsilateral stroke within 30 days 
of the operation and during subsequent follow-up. We 
excluded transient ischaemic attacks as these are of little 
clinical consequence; (c)who had known occlusion of 
the operated artery (defined by ultrasound, angio- 
graphy, or exploration of the artery) within 30 days of 
the operation; (d) who had a significant complication 
related to surgery such as haemorrhage from or rupture 
of the artery, infection of the endarterectomy site, cranial 
nerve palsy or pseudoaneurysm formation; and (e) who 
developed a greater than 50% restenosis or occlusion 
(defined by ultrasound or angiography) of the operated 
artery during follow-up. All data were independently 
extracted by two reviewers (RS, CC) and cross-checked. 
In addition, we collected etails about he patients in- 
cluded in the trial, the inclusion and exclusion criteria, 
the comparability of the treatment and control groups 
for important prognostic factors, details of the surgical 
technique and the use of antiplatelet therapy during 
follow-up. If any of the above data were not available 
from the publication, we sought further information 
from the trialists. 
In some trials the artery was randomised rather 
than the patient, ~s-22 and it was therefore possible for 
patients undergoing bilateral endarterectomies to have 
each artery randomised to a different procedure. This 
made analysis of the results difficult for two reasons. 
Firstly, in patients who had both patching and primary 
closure (particularly those having simultaneous bi- 
lateral operations), it would be difficult o relate death 
or any stroke (as opposed to ipsilateral stroke) to one 
particular procedure. We therefore decided to analyse 
death and any stroke only in those who had unilateral 
procedures or who had the same procedure to both 
arteries. These data were not available from one trial. 19 
Secondly, although the analyses of arterial com- 
plications and of ipsilateral strokes could be performed 
for each artery rather than each patient, these analyses 
are flawed. They assume that, in patients with bilateral 
endarterectomies, vents in each carotid artery were 
independent which is unlikely to be true. However, 
since only 10% of patients had bilateral procedures, 
we felt it reasonable to perform these analyses. 
Intention-to-treat analyses were not possible since 
outcome data were not available for about 40 patients 
who were lost to follow-up. For the main analyses, 
we assumed that patients who were lost did not have 
an outcome vent, but where statistically significant 
results were found we performed worst case sensitivity 
analyses to assess if the results were robust. These 
analyses assumed that all patients lost from the patch- 
ing arm had an adverse outcome, whereas none of 
those lost from the control arm did. 
Proportional risk reductions were calculated based 
on a weighted estimate of the odds ratio using the 
Peto method. R3Since all the outcome vents assessed 
were rare, the odds ratios quoted will be similar 
to the relative risks. Absolute risk reductions were 
calculated from the crude risks of each outcome in all 
trials combined. 23Heterogeneity between trial results 
was tested using the standard Chi-squared test. 
Results 
Six trials comparing routine patching with primary 
closure were included (794 patients, 882 op- 
erations), ls-RR'24-26 Two other studies were excluded. In 
one unpublished trial, results were not available for 
100 out of the 302 patients initially randomised because 
they did not receive their allocated operationY An- 
other trial identified in the discussion section of one of 
the published papers, 24 turned out to be non-random. 28 
One trial had three arms - saphenous vein patching, 
polytetrafluoroethylene (PTFE) patching and primary 
closure, z9 In the analysis of patch versus no patch, 
the two patching arms were combined, whilst in the 
analysis of venous versus ynthetic patches they were 
considered separately. Two other trials comparing dif- 
ferent patches were included (326 operations). ~4'29 An- 
other such trial was excluded because no data on 
clinical outcomes and arterial complications were 
available ven after contacting the authors. 3°
Methodological quality of included studies 
There were significant flaws in most of the trials. 
In four trials, the randomisation sequence was well 
concealed using sealed, opaque, sequentially 
numbered envelopes. I9-21'29 In the four other trials the 
randomisation sequence was less secure which may 
have allowed some selection bias15; two were ran- 
domised but used poor methods of concealment (non 
opaque, un-numbered envelopes I8 and an open ran- 
dom number list14), and the other two used quasi- 
random allocation based on the patient's hospital num- 
ber 24 or social security number. R6
Adequate blinding may be important in order to 
reduce bias in the detection of certain outcome vents 
such as minor strokes or the ultrasound assessment 
of restenosis. Correspondence with the authors con- 
firmed that clinical assessment was definitely blinded 
in only two trials, I8'2° but that restenosis was assessed 
blind in all except two trials. 19'26 True intention-to- 
treat analysis was only possible for two trials after 
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Table 1. Characteristics of trials included in this review. 
Trial Year No. of Mean Sex Asympto- Treatment Control Shunt- Anaes- Duration 
patients age (% matic ing (%) thetic of FU 
(no. opera- (years) male) disease 
tions) (%) 
Vleeschauwer 1987 150 (174) 64 70 30 SV PC 100 GA 1 year 
et al. TM 
Eikelboom 1988 126 (129) 63 73 18 SV PC 20 GA Mean 5 years 
et al. 24'25 
Clagett et aI. 21'~2 1989 109 (126) 62 99 23 SV PC 100 GA 4-5 years 
Lord et al. 19 1989 123 (140) 63 62 ? SV or PTFE* PC 17 GA Hospital 
discharge 
Ranaboldo 1993 199 (213) 66 69 8 SV or Dacron PC ? GA 1 year 
et al. 2° 
Katz et al. 26 1994 87 (100) 67 56 40 PTFE PC 100 GA Mean 29 
months 
Gonzalez- 1994 84 (95) 69 88 28 PTFE SV 100 GA Mean 29 
Fajardo 14 months 
Ricco et al. 29 1994 124 (141) 63 80 33 PTFE SV 83 GA Mean 53 
months 
FU=follow-up; PC=primary closure; GA=general anaesthetic; *Randomly allocated; SV=Saphenous vein patch; PTFE=Poly- 
tetrafluoroethylene patch; ? =Unknown. 
additional data were obtained from the authors. 14'2° In 
the other trials, data on a total of 48 patients who were 
lost to follow-up were not available, and in one trial 
four patients who did not have the procedure that 
they were randomised to receive were excluded from 
the analysis. I9 
In all trials in which the data were available, the 
treatment groups were comparable for important prog- 
nostic factors such as age, sex, vascular isk factors, 
and the percentage of patients undergoing operation 
for asymptomatic disease. In all except one trial the 
follow-up was at least 12 months, and most of the 
patients received antiplatelet or anticoagulant drugs 
long term after the operation. 
Other characteristics ofincluded studies 
diameter was less than 3.5 mm. 26 In the remaining 
trials, only one patient randomised toprimary closure 
required a patch because the artery was felt to be too 
narrow. 24 Five other patients randomised to primary 
closure required patching either because the stenosis 
was very high (one patient) or because the artery 
became occluded postoperatively (four patients). 
Three patients from the patch group did not receive 
a patch either because no vein was avaiiable or because 
rapid closure was required ue to cerebral ischaemic 
changes inferred from EEG monitoring. 
Three trials compared PTFE patching with sa- 
phenous vein patching. 14'19'29 One trial only included 
patients with narrow internal carotid arteries (<3.5 mm 
internal diameter), 29 and two only provided data on 
ipsilateral strokes. 19'29 
Details of the trials are given in Table 1. In the six 
trials of patching versus primary closure, the average 
age of patients was about 65 years and about 60-70% 
were male. Three of these trials compared saphenous 
vein patches with primary c losure ,  1s'21'24 one  PTFE 
patches with primary closure, 26 one randomised be- 
tween vein patching, PTFE patching or primary clos- 
ure, 19 and one left the choice of patch material (either 
vein or Dacron) up to each surgeon. 2°In this trial, the 
results were not recorded by the type of patch that the 
patient received. Two trials excluded narrow carotid 
arteries before randomisation  the basis that it was 
not safe to close these with primary closure: in one 38 
out of 163 arteries were excluded because the internal 
diameter was less than 5 mm, 21'22 whilst in the other, 
one patient out of 110 was excluded because the arterial 
Statistical analyses 
The results presented may differ from those in the 
published reports where additional information has 
been obtained from the authors. There was no stat- 
istical heterogeneity in any of the analyses. 
A. Routine patch versus primary closure 
(i) Perioperative period 
Patching was associated with a statistically significant 
66% reduction in the relative odds of ipsilateral isch- 
aemic or haemorrhagic stroke within 30 days of sur- 
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(a) No. events/no, entered 
Patch Primary 
closure 
Venous patch 
Vleeschauwer 1987 
Eikelboom 1988 
Clagett 1989 
Lord 1989 
Subtotal 
No events 
2/67 4/62 
0/62 1/64 
0/43 3/50 
2/262 8/260 
Synthetic patch 
Lord 1989 1/47 3/50 
Katz 1994 1/49 2/51 
Subtotal 2/96 5/101 
Venous or synthetic 
Ranaboldo 1993 2/109 6/104 
Total 6/467 19/465 
0.01 0.1 
Patch better Primary 
closure better 
Odds ratio (95% C1) 
OR 0.34 
(95% C1 0.15-0.76) 
[ 
10 
(b) No. events/no, entered 
Patch Primary 
closure 
Patch better Primary 
closure better 
Venous patch 
Vleeschauwer 1987 No events 
Eikelboom 1988 2/67 5/62 
Clagett 1989 1/62 2/64 
Subtotal 3/219 7/210 
Synthetic patch 
Katz 1994 1/49 2/51 
Venous or synthetic 
Ranaboldo 1993 2/109 7/104 
OR 0.38 
16/365 • (95% C1 0.16-0.88) 
0.01 0.1 1 10 
Odds ratio (95% C1) 
Total 6/377 
Fig. 1. Effect of routine patching compared to primary closure (log scale for odds ratio; horizontal lines are 95% confidence intervals). 
(a) Ipsilateral stroke within 30 days of surgery. (b) Ipsilateral stroke at the end of follow-up. Graphical representation f the results of 
each trial and the recta-analyses forthe two primary outcomes. 
gery  (2p = 0.008) (Fig. 1). The numbers  were  smal l  and 
so the conf idence interval  was  very  wide;  on ly  25 out  
of 932 operat ions  resu l ted in a per ioperat ive  ips i lateral  
stroke (2.7%). S imi lar  odds  reduct ions  were  seen w i th  
patch ing  for any  per ioperat ive  stroke ( ipsi lateral ,  
contra latera l  or bra instem) and for any  per ioperat ive  
stroke or death  (Fig. 2), a l though the latter was  not  
signif icant. There were  on ly  six per ioperat ive  deaths,  
three of wh ich  were  due  to stroke. If conf i rmed,  the 
potent ia l  abso lute  reduct ions  in ips i latera l  stroke and  
any  stroke or death  w i th  patch ing  are cl inical ly im- 
por tant  (Table 2). 
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(a) 
No, events/no, entered 
Patch Primary 
closure 
Any stroke 5/313 13/307 
Death from all causes 3/313 3/307 
Stroke or death 7/313 14/307 
Arterial occlusion 1/377 15/381 
Wound haemorrhage 5/467 3/465 
Neck/arterial infection 1/377 0/365 
Cranial nerve palsy 1/111 4/115 
(b) 
I 
0.1 
No. events/no, entered 
Patch Primary 
closure 
Patch better 
Odds ratio (95% C1) 
Primary 
closure better 
Patch better 
I_ 
10 
Any stroke 7/313 18/307 • 
Odds Ratio 
(95% C1) 
0.38 (0.15-0.97) 
0.93 (0.18-4.65) 
0.47 (0.20-1.13) 
0.17 (0.06-0.46) 
1.60 (0.39-6.47) 
7.70 (0.15-99.99) 
0.77 (0.17-3.50) 
Primary Odds Ratio 
closure better (95% C1) 
0.38 (0.17-0.85) 
Death from all causes 44/313 58/307 = 0.67 (0.43-1.04) 
Stroke or death 50/313 72/307 
Arterial restenosis 17/377 48/365 
>50%/occlusion I 
0.1 
Odds ratio (95% C1) 
0.58 (0.38-0.88) 
0.32 (0.19-0.53) 
I 
10 
Fig. 2. Effect of routine patching compared to primary closure (log scale for odds ratio; horizontal lines are 95% confidence intervals). (a) 
Other outcomes within 30 days of surgery. (b) Other outcomes at the end of follow-up. Graphical representation f the results of the 
meta-analyses forother important outcomes. 
Table 2. Potential absolute benefits of routine patching compared 
to primary closure (95% confidence intervals). 
Within 30 days Long term 
(about 3 years) 
Ipsilateral stroke* 28 (9-39) 28 (4-36) 
Any stroke or deatht- 24 ( -5 -37)  75 (24-130) 
* Events prevented by patching per 1000 operations. 
f Events prevented by patching per 1000 patients. 
Few arter ial  compl icat ions  occurred w i th in  30 days  
of surgery  (Fig. 2). Acute  arter ia l  occlus ion was  sys- 
temat ica l ly  looked for in all pat ients  in five tr ials us ing 
dup lex  u l t rasound,  2°'26 in t ravenous  dig i ta l  subtract ion 
ang iography,  19'24 or ocular  pneumoplethysmography .  21 
Patching led to an 83% reduct ion  in the odds  of 
occlus ion (2p = 0.0005), the absolute r isks of occlusion 
be ing 1/377 (0.3%) w i th  patch ing  and  15/381 (3.9%) 
w i th  pr imary  closure. However ,  26 arter ies (14 patch,  
12 pr imary  closure) were  not  assessed for occlus ion 
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in the early postoperative p riod. In the unlikely event 
that all unscanned arteries in the patched group had 
occluded while all those in the primary closure group 
had not (worst case analysis), the result became non- 
significant (OR 1.01, 95% CI 0.48-2.12). There were too 
few other perioperative complications toreliably detect 
any differences between patching and primary closure. 
(ii) Long-term follow-up 
Patching also appeared to be associated with fewer 
ipsilateral strokes during long-term follow up than 
primary closure (1.6% vs. 4.4%, 2p=0.02, Figure 1), 
and with a lower risk of long-term restenosis (>50%) 
or occlusion as defined by duplex ultrasound (4.5% 
vs. 13.2%, 2p<0.0001, Fig. 2). However, 53 arteries (27 
patch, 26 primary closure) were lost to follow-up, and 
the benefits were no longer seen in the worst case 
analyses implying they are not statistically robust. 
There was a 62% reduction (2p=0.02) in the odds of 
any stroke and 42% reduction (2p = 0.01) in the odds 
of any stroke or death during follow-up (Fig. 2) but 
again these benefits were no longer seen if losses to 
follow-up were accounted for in a worst case analysis. 
The potential reductions in ipsilateral stroke and any 
stroke or death are again clinically significant (Table 
2). 
We also performed several sensitivity analyses 
which showed that there were no significant dif- 
ferences in any of the results between: trials that used 
well concealed methods of randomisation and those 
that did not; trials that used blinded assessments 
versus those that did not; different ypes of patch. We 
also wished to assess whether there was any evidence 
that the effect of patching differed depending on the 
duration of follow-up and, therefore, we compared 
the results at I year of follow-up with those at the end 
of follow-up which were available in three trials. I8'2°'24 
For each outcome, the odds ratios for results at 1 year 
were very similar to those at the end of follow-up. 
B. Synthetic versus venous patches 
There were too few events to determine whether there 
were important differences between synthetic and ven- 
ous patches in the risks of ipsilateral stroke, stroke 
or death, or arterial complications during either the 
perioperative period or during follow-up (Fig. 3). PTFE 
patches appeared to be associated with fewer pseudo- 
aneurysms during follow-up. However, only one trial 
provide a definition of pseudoaneurysm (any di- 
latation of the artery greater than 50% of the original 
patch diameter 29) and the clinical significance of the 
reduced risk with PTFE patching was unclear. No 
pseudoaneurysms ruptured or were associated with 
ipsilateral strokes, and in one trial all dilatations ap- 
peared within 1 month of surgery and none were 
progressive. 14 
In two trials, PTFE patching was associated with 
operation times that were about 10-15 rain longer than 
vein patching. 14'29 In both cases this was due to longer 
haemostasis times with PTFE patching due to bleeding 
from suture holes. The trial that was excluded because 
of the lack of clinical data, s° also reported that the time 
from release of the clamps to the end of the operation 
was significantly longer with PTFE patches compared 
to either vein patching or Dacron patching because of 
excessive bleeding. 
Discussion 
There appeared to be promising and potentially clin- 
ically important rends in favour of routine patching 
in terms of reductions in the risks of ipsilateral stroke, 
any stroke, and any stroke or death both during the 
perioperative period and during long term follow-up. 
However, these results may not be at all reliable and 
must be interpreted with caution for several reasons. 
Firstly, they were based on a very small number of 
outcome events (25 strokes and 102 deaths in total) 
and are, therefore, not statistically robust. A recent 
example highlights the dangers of relying on a meta- 
analysis which included small numbers of outcomes; 
a systematic review of the use of magnesium in acute 
myocardial infarction showed a large and highly stab 
istically significant reduction in death based on only 
a few hundred patients which was not confirmed in 
a mega-trial of 50 000 patients. 31 The results of our 
review are also limited by losses to follow-up and 
poor methodological quality of the trials. In addition, 
since no unpublished study has been included, it is 
also possible that publication bias has exaggerated the 
potential benefit. 32 
The data on arterial occlusions and restenosis are 
again promising but not conclusive and are less rel- 
evant han data on clinically important outcomes such 
as stroke. Acute postoperative occlusion, though 
feared, is not always associated with stroke, and nei- 
ther is late restenosis. In one study, patients with 
restenosis >50% had a better long term prognosis in 
terms of death or stroke than patients with no sig- 
nificant restenosis! 6 
Most surgeons would agree that carotid patching 
does play a role in carotid endarterectomy since they 
are faced with situations when this type of closure is 
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(a) 
No. events/no, entered 
Synthetic Venous 
Ipsilateral stroke 2/165 1/161 
Any stroke 1/92 1/93 
Death from all causes 2/92 1/93 
Stroke or death 3/92 1/93 
Arterial occlusion 2/165 1/161 
Wound haemorrhage 1/165 1/161 
Neck/arterial infection No events 
Cranial nerve palsy 1/50 1/45 
(b) 
Synthetic better Venous better 
0.1 1 
Odds ratio (95% C1) 
Odds Ratio 
(95% C1) 
1.87 (0.19-18.04) 
0.99 (0.06-15.90) 
2.01 (0.21-19.48) 
2.73 (0.38-19.66) 
1.99 (0.21-19.28) 
0.98 (0.06-15.76) 
0.90 (0.06-14.64) 
I 
10 
No. events/no, entered Synthetic better Venous better 
Synthetic Venous 
Ipsilateral stroke 5/118 5/118 q 
Any stroke 5/92 5/93 t 
L Death from all causes 11/92 12/93 
Stroke or death 14/92 15/93 
Arterial restenosis 6/118 5/118 
>50%/occlusion 
Pseudoaneurysm 1/118 14/118 -~ " 
r 
0.i 
Odds ratio (95% C1) 
Odds Ratio 
(95% C1) 
1.06 (0.30-3.78) 
1.08 (0.30-3.89) 
0.96 (0.40-2.33) 
0.98 (0.44-2.20) 
1.26 (0.38-4.24) 
0.15 (0.05-0.44) 
I 
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Fig. 3. Effect of synthetic ompared to venous patch closure (log scale for odds ratio; horizontal lines are 95% confidence intervals). 
(a) Outcomes within 30 days of surgery. (b) Outcomes at the end of follow-up. Graphical representation fthe results of the meta-analyses 
for the trials comparing synthetic versus venous patching. 
either unavoidable or posit ively desirable, e.g. an ar- 
tery with a very nar row internal diameter or a very 
long plaque. 24 However ,  it is unclear how frequently 
such situations arise and how narrow an artery should 
be before it has to be patched. For example, only two 
trials in this review excluded narrow arteries on the 
grounds  that they must  be patched. One trial excluded 
23% of arteries because they were less than 5 mm 
diameter, 21 whilst another trial excluded only 1% of 
arteries because they were less than 3.5 mm diameter76 
In the other trials, very few patients had to cross over 
f rom pr imary  closure to patching because the artery 
was deemed too narrow for pr imary closure. The trials 
of patching versus pr imary closure included in this 
review tested the pol icy of rout inely patching all ar- 
teries against a pol icy of never patching in those 
patients in whom there was no definite indication for 
a patch. A pol icy of selective patching of only those 
arteries thought  to require a patch at the t ime of 
operat ion compared to no patching has not been tested 
in RCTs. 
It is possible that if patching is effective that its 
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benefit may be more marked in narrow arteries or 
possibly restricted to narrow arteries. 33 The exclusion 
of some narrow arteries from trials in this review may 
then have biased the results towards primary closure. 
This would be analagous to carotid endarterectomy 
for symptomatic carotid stenosis where the benefit is 
restricted to those with severe artery stenosis. 1'2's4 We 
were unable to test this hypothesis because the results 
of the trials were not reported according to the degree 
of narrowing of the artery. The results of the trial that 
did exclude a significant number of arteries because 
they were less than 5 mm diameter were no worse 
than those of the other trials. 21"22 This might suggest 
that there is little difference in the effect of patching 
between arteries greater than or less than 5 mm dia- 
meter. However, such indirect comparisons between 
trials are unreliable. 
There was insufficient evidence ither from indirect 
comparisons or direct randomised comparisons to fa- 
vour the use of one type of patch over another. The 
risk of major arterial complications such as rupture or 
infection was so low (<1%) that, to reliably detect a 
50% reduction in the risk of these complications with 
synthetic patching, a trial would need to recruit over 
10 000 arteries (c~ = 0.05, fi = 0.20). If the risks of stroke 
and major arterial complications were shown to be 
similar for synthetic and venous patches, some sur- 
geons may prefer to use synthetic patches because it 
leaves the vein for possible coronary bypass grafting 
later and spares the patient discomfort due to vein 
harvesting. Four thousand arteries would still be re- 
quired to show that synthetic patching was associated 
with no worse than a 1% increase in the risk of 
perioperative ipsilateral stroke compared to venous 
patching assuming a 4% risk of ipsilateral stroke (c~ = 
0.05, fl = 0.20). 
PTFE patching does appear to increase the time for 
haemostasis which may be less of a problem with 
Dacron. B° One study also showed that surgeons pre- 
ferred the handling qualities of Dacron or vein to 
PTFE. B° Dacron may therefore be preferable to PTFE 
although some people believe it carries a greater isk 
of thrombosis and it may be more prone to infection. 19 
Implications for practice 
At present most vascular surgeons do not routinely 
use patching in all patients undergoing carotid en- 
darterectomy. Given the limitations of the data, the 
results of this review cannot support a firm re- 
commendation i favour of routine patching. Much 
more conclusive evidence is required before a re- 
commendation implying such a substantial change 
in practice can be made. Individual surgeons (and 
patients) may, however, interpret the evidence dif- 
ferently. However, the results of the review do favour 
a more liberal approach to the use of patching than is 
currently practised. The use of selective patching (e.g. 
for very narrow arteries) has not been studied in RCTs 
and so no clear indications for selective patching can 
be given. The results of this review do not conclusively 
support he use of one type of patch material over any 
other in carotid endarterectomy. 
Implications for research 
The potential benefit of routine patching could be 
clinically important but in order to have reliable evi- 
dence on the risks and benefits of patching compared 
to primary closure, a large multicentre randomised 
controlled trial will be required. This trial should 
concentrate on clinical outcomes uch as any stroke 
(particularly fatal or disabling stroke), ipsilateral stroke 
and death, and have long-term follow-up. The trial 
would need to recruit about 3000 patients to have an 
80% chance of detecting a reduction in the absolute 
risk of the composite outcome of perioperative stroke 
or death from 5% to 2.5%, and a 90% chance of 
detecting a reduction in the risk of stroke or death at 
5 years from 25% to 20%. The trial should use a secure 
method of randomisation and be analysed on a truly 
intention-to-treat basis with complete follow-up of 
all patients. Patients rather than arteries should be 
randomised so that the number of deaths and strokes 
are reported on a patient basis. Clinical follow-up 
should be blinded with independent assessment of 
strokes, preferably by neurologists. B5 The results 
should be analysed according to the degree of nar- 
rowing of the artery and whether the patient had a 
symptomatic stenosis or not. Such a trial would be 
worthwhile as it should be relatively inexpensive and 
provide a definitive answer about the role of routine 
patching as well as providing important information 
on the opt imum use of selective patching. A factorial 
design would allow some other intervention to be 
tested simultaneously, such as routine shunting. Until 
the benefit of carotid patching in terms of clinical 
outcomes for the patient is established, any future trials 
should include a control group of primary closure. 
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